I love the challenges of working with technology and life sciences companies as they evolve from startups to public companies.
mballantyne@cooley.com
Mark Ballantyne focuses his practice on representing IPO ready and publicly traded life sciences and technology companies, as well as underwriters.
Download full bio
BigCommerce Holdings – $345 Million Convertible Senior Notes Offering
Sensei Biotherapeutics – $133 Million IPO
Orphazyme – $84 Million IPO
Legend Biotech - $487 Million IPO
LogicBio Therapeutics – $80.5 Million IPO
View all
Public Companies
Capital Markets
Life Sciences
Technology
Golfing
Traveling
University of Richmond School of LawJD, magna cum laude, Order of the Coif, McNeill Law Society, 2012
Wake Forest UniversityBA, 2008
Virginia
Cooley Elects 28 New Partners for January 1, 2022 November 29, 2021
Cooley Advises Meredith on $3.5 Billion of Debt Financings February 5, 2018
Valeritas – $53 Million IPO April 7, 2017
Best Lawyers: Ones to Watch - Securities/Capital Markets Law and Venture Capital Law (2021)
+1 703 456 8084
Locations